Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Sales and Option Exercise
SEC Form 4 Filing
Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reported the exercise of stock options and subsequent sale of common stock on July 1, 2024, according to a Form 4 filing with the SEC.
Summary
- On July 1, 2024, Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options to acquire 1,667 shares of common stock at a price of $21.41 per share.
- Simultaneously, Eydelman sold 913 shares at a weighted average price of $75.9272 (ranging from $75.43 to $76.39) and 754 shares at a weighted average price of $76.8998 (ranging from $76.58 to $77.085).
- Following these transactions, Eydelman directly owns 30,826 shares of Vaxcyte common stock and holds options for 183,331 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity. The transactions appear to be part of a pre-planned strategy.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned well in advance.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans. The impact on the stock price is usually minimal unless the transactions are unusually large or frequent.
Comparison to Industry Standards
- Insider transactions are a normal part of corporate governance and are regularly disclosed by executives at publicly traded companies.
- Similar filings are made by executives at companies like Moderna (MRNA) and BioNTech (BNTX), which are also in the biotechnology sector.
- The use of Rule 10b5-1 trading plans is a common practice to avoid accusations of insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely to be minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 2023-06-29 | Date of adoption of Rule 10b5-1 trading plan. |
| 2023-04-01 | Initial vesting date for stock options. |
| 2032-05-08 | Expiration date of stock options. |
| 2024-07-01 | Date of stock option exercise and stock sales. |
| 2024-07-02 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.